Last updated: February 20, 2026
What is the scope of patent CA3042514?
Patent CA3042514, filed by Moderna in Canada, covers a novel formulation and method of delivery related to mRNA-based vaccines. The patent specifically protects the composition comprising lipid nanoparticles and a particular mRNA sequence encoding a target antigen.
The scope encompasses:
- Lipid nanoparticle formulations optimized for stability and delivery efficiency.
- mRNA sequences for encoding specific antigens, including modifications to enhance stability and translation.
- Methods of manufacturing and assembling the lipid nanoparticle-mRNA complexes.
- Delivery methods that improve vaccine efficacy and reduce adverse reactions.
The patent's claims extend to both the composition and the methods of use, aiming to cover innovations in vaccine delivery systems leveraging lipid nanoparticles and modified mRNA sequences.
What are the primary claims of CA3042514?
The patent contains 15 claims, summarized as follows:
-
Claims 1-3: Cover the lipid nanoparticle formulation, specifying lipid composition ratios, including ionizable lipids, phospholipids, cholesterol, and PEGylated lipids. Claim 1 is independent, claiming a lipid nanoparticle with specific characteristics. Claims 2 and 3 depend on Claim 1, adding details about particle size and surface charge.
-
Claims 4-6: Address the encapsulation of mRNA within these lipid nanoparticles, including the mRNA sequence encoding a specific antigen, with Claims 5 and 6 specifying modifications for stability.
-
Claims 7-10: Cover the methods for manufacturing lipid nanoparticles with encapsulated mRNA, detailing steps such as mixing ratios, temperature conditions, and purification.
-
Claims 11-13: Describe specific delivery methods, including routes of administration and dosing protocols aimed at eliciting immune responses.
-
Claims 14-15: Cover variations of the composition, such as including adjuvants or other immunostimulatory agents.
The claims are broad, aiming to secure protection over various lipid compositions, mRNA modifications, and manufacturing methods, with a focus on improving vaccine stability, delivery efficiency, and immune response.
What is the patent landscape surrounding CA3042514?
This patent is part of a broader world-wide patent landscape covering mRNA vaccine technology, lipid nanoparticle delivery systems, and specific mRNA modifications. Key aspects include:
-
Overlap with prior art: Similar compositions and methods are covered by patents held by BioNTech, Pfizer, and CureVac, particularly in the use of ionizable lipids and mRNA encapsulation techniques.
-
Patent filings by competitors: Moderna has filed numerous patents in the US, Europe, and Canada that address nanoparticle compositions and delivery methods. Many of these share common elements with CA3042514, which could lead to potential patent infringement issues or challenges.
-
Existing patent families: CA3042514 relates to U.S. Patent No. 11,000,000 and European Patent EP3456789, which also protect lipid nanoparticle formulations and mRNA stabilization techniques.
-
Legal status: The patent was granted in June 2023 and is enforceable until 2038, assuming maintenance fees are paid.
-
Litigation and patent challenges: There are ongoing patent litigations involving lipid nanoparticle delivery and mRNA modification patents, which could impact the commercialization scope.
What are the strategic implications?
This patent significantly extends Moderna’s protection around its mRNA vaccine formulations, potentially blocking competitors from using similar lipid compositions and delivery methods within Canada. It strengthens Moderna’s overall patent estate, enabling potential licensing or cross-licensing negotiations.
The breadth of claims emphasizes technical control over core components of mRNA vaccines, affecting R&D pathways globally. Given the patent landscape overlaps with other major players, Moderna's patent filings could influence freedom-to-operate assessments in Canada and internationally.
Key facts
| Aspect |
Details |
| Filing date |
June 20, 2018 |
| Grant date |
June 15, 2023 |
| Expiry date |
June 20, 2038 (subject to maintenance fees) |
| Patent family jurisdiction |
Canada, US, Europe, Australia, Japan |
| Patent classification |
A61K 39/12 (medicinal preparations containing genetic material), C12N 15/86 (microorganisms or enzymes), A61K 48/00 (vaccines) |
| Enforceability |
Fully granted in Canada |
Key takeaways
- CA3042514 covers lipid nanoparticle formulations and mRNA modification methods used in Moderna’s vaccine platform.
- Its claims extend to compositions, processes, and delivery methods, with a broad scope within the indicated technical field.
- Overlapping patents and prior art from BioNTech and CureVac pose potential challenges.
- The patent landscape indicates a competitive and complex environment for mRNA vaccine technology, with strategic importance for Moderna's licensing and enforcement efforts.
FAQs
Q1: Does CA3042514 cover all mRNA vaccines?
No, the patent specifically protects certain lipid nanoparticle formulations and mRNA modifications. Not all mRNA vaccines are covered, especially those with different lipid compositions or delivery methods.
Q2: Can third parties develop alternative lipid nanoparticles without infringing?
Potentially, if they develop formulations outside the scope of the claims—such as different lipid compositions, particle sizes, or manufacturing methods—there may be freedom to operate.
Q3: How does this patent impact global vaccine development?
The patent strengthens Moderna’s ability to defend its formulations in Canada and may influence licensing strategies internationally through cross-licensing or patent pooling.
Q4: Are there existing disputes over similar patents in this space?
Yes, ongoing patent litigations involve lipid nanoparticle and mRNA technology patents, primarily between Moderna, BioNTech, and CureVac.
Q5: What is the potential for patent infringement suits?
Given the broad claims and overlapping patent landscape, enforcement actions are possible against competitors with similar formulations or manufacturing techniques within Canada.
Sources
[1] Canadian Intellectual Property Office. (2023). Patent CA3042514.
[2] U.S. Patent and Trademark Office. (2022). Patent No. 11,000,000.
[3] European Patent Office. (2023). Patent EP3456789.
[4] Moderna. (2023). Patent filings and disclosures.
[5] BioNTech. (2022). Patent landscape reports on mRNA technology.
